Search Results

You are looking at 1 - 10 of 41 items for :

  • "glucocorticoid treatment" x
  • Refine by Access: All content x
Clear All
Open access

Filippo Ceccato, Elisa Selmin, Giorgia Antonelli, Mattia Barbot, Andrea Daniele, Marco Boscaro, Mario Plebani, and Carla Scaroni

, and drafting the manuscript. They all approved the final version of the paper. References 1 Ceccato F Scaroni C . Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment . Clinical Chemistry and

Open access

Muriel Houang, Thao Nguyen-Khoa, Thibaut Eguether, Bettina Ribault, Séverine Brabant, Michel Polak, Irène Netchine, and Antonin Lamazière

was eventually positively diagnosed thanks to liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), which allowed the quantitation of endogenous steroid metabolites and the identification of exogenous glucocorticoid treatment on a

Open access

Brijesh Krishnappa, Ravikumar Shah, Saba Samad Memon, Chakra Diwaker, Anurag R Lila, Virendra A Patil, Nalini S Shah, and Tushar R Bandgar

-line modality to delineate the impact of the route, dose, and duration of glucocorticoid treatment on the clinical, hormonal, radiological outcomes. Methods This retrospective study was conducted after obtaining approval from Institutional Ethics

Open access

Ida Staby, Jesper Krogh, Marianne Klose, Jonas Baekdal, Ulla Feldt-Rasmussen, Lars Poulsgaard, Jacob Bertram Springborg, and Mikkel Andreassen

) and it is not without risk to perform ITT in the perioperative phase. Thus, several approaches have been suggested, ranging from routine use of prophylactic glucocorticoid treatment to glucocorticoid sparing regimens with close observation and only

Open access

Anastasia P Athanasoulia-Kaspar, Matthias K Auer, Günter K Stalla, and Mira Jakovcevski


Patients with non-functioning pituitary adenomas exhibit high morbidity and mortality rates. Growth hormone deficiency and high doses of glucocorticoid substitution therapy have been identified as corresponding risk factors. Interestingly, high levels of endogenous cortisol in, e.g., patients with post-traumatic stress disorder or patients with Cushing’s disease have been linked to shorter telomere length. Telomeres are noncoding DNA regions located at the end of chromosomes consisting of repetitive DNA sequences which shorten with aging and hereby determine cell survival. Therefore, telomere length can serve as a predictor for the onset of disease and mortality in some endocrine disorders (e.g., Cushing’s disease).


Here, we examine telomere length from blood in patients (n = 115) with non-functioning pituitary adenomas (NFPA) in a cross-sectional case–control (n = 106, age-, gender-matched) study using qPCR. Linear regression models were used to identify independent predictors of telomere length.


We show that patients with NFPA exhibited shorter telomeres than controls. No significant association of indices of growth hormone deficiency (IGF-1-level-SDS, years of unsubstituted growth hormone deficiency etc.) with telomere length was detected. Interestingly, linear regression analysis showed that hydrocortisone replacement dosage in patients with adrenal insufficiency (n = 52) was a significant predictor for shorter telomere length (β = 0.377; P = 0.018) independent of potential confounders (gender, age, BMI, arterial hypertension, systolic blood pressure, number of antihypertensive drugs, total leukocyte count, waist-to-hip ratio, waist circumference, diabetes mellitus type 2, HbA1c, current statin use). Median split analysis revealed that higher hydrocortisone intake (>20 mg) was associated with significantly shorter telomeres.


These observations strengthen the importance of adjusted glucocorticoid treatment in NFPA patients with respect to morbidity and mortality rates.

Open access

Wiebke Arlt and the Society for Endocrinology Clinical Committee

patients who receive chronic exogenous glucocorticoid treatment with doses ≥5 mg prednisolone equivalent for more than 4 weeks. This may also be caused by long-lasting glucocorticoid injections into joints or chronic application of glucocorticoid cream or

Open access

Ditte Sofie Dahl Sørensen, Jesper Krogh, Åse Krogh Rasmussen, and Mikkel Andreassen

doses of glucocorticoids ( P  < 0.001), with the difference remaining significant after surface area adjustment ( P  = 0.002) ( Table 2 ). The median duration of glucocorticoid treatment in the entire cohort was 24 (IQR 16 to 46) years. Treatment

Open access

Helga Schultz, Svend Aage Engelholm, Eva Harder, Ulrik Pedersen-Bjergaard, and Peter Lommer Kristensen

dose (mg), mean (min–max) 247 (83–563) 240 (100–304) 255 (83–563) 259 (150–300) Previous glucocorticoid treatment (%)  None 75 (57) 43 (57) 23 (58) 9 (56)  In relation to chemotherapy 26 (20) 17 (23) 6 (15

Open access

Eva Novoa, Marcel Gärtner, and Christoph Henzen

frequency of the glucocorticoid treatment of this disorder. In animal studies, intratympanic dexamethasone (IT-Dex) infusions resulted in higher perilymph concentrations than intravenous dexamethasone application without any systemic absorption (10) . By

Open access

L M Mongioì, R A Condorelli, S La Vignera, and A E Calogero

with central adrenal insufficiency. Case no. Sex Age (years) Etiology Other hormonal deficiencies and/or comorbidities Previous glucocorticoid treatment Other hormonal treatment Length of treatment (months) 1 F 49